AGC (JP:5201) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AGC Inc. has recorded significant impairment losses of 118.3 billion yen due to a downturn in its biopharmaceuticals CDMO business, leading to a downward revision of its full-year financial forecasts for 2024. Operating profit is projected to fall, influenced by sluggish sales in the biopharmaceuticals sector and a slowing European economy, although net sales forecasts remain unchanged due to strong electronic materials shipments. Despite these setbacks, the dividend forecast is not affected.
For further insights into JP:5201 stock, check out TipRanks’ Stock Analysis page.